Children's Cancer Institute financial statement 2025

	2023	2024	2025
	$	$	$
PROFIT & LOSS			
Revenue			
Research	59,158,176	55,786,012	67,006,294
Fundraising	21,376,057	27,656,927	29,238,540
Other	2,398,631	2,898,099	2,278,911
Total	**82,932,864**	**86,341,038**	**98,523,745**
Expenses			
Research and Scientific Activities	69,918,375	70,031,364	77,035,272
Fundraising	9,172,172	7,884,673	8,696,905
Support and Administration	9,312,309	10,248,588	10,721,696
Total	**88,402,856**	**88,164,625**	**96,453,873**
Surplus/(Deficit) for the Year	**(5,469,992)**	**(1,823,587)**	**2,069,872**
Cost of fundraising (direct) %	32%	18%	23%
BALANCE SHEET			
Cash and cash equivalents	26,635,600	17,151,343	12,842,000
Financial assets	27,494,599	30,260,182	19,093,461
Trade receivables	13,149,215	6,855,422	28,722,931
Total Assets	**81,765,645**	**68,800,044**	**78,071,738**
Total Liabilities	**50,509,556**	**37,365,463**	**44,567,289**
Equity	**31,256,089**	**31,434,581**	**33,504,449**

Children's Cancer Institute

Children’s Cancer Institute financial statement 2025

Children’s Cancer Institute delivered strong financial performance in 2025, with total revenue increasing by 14% to $98.5 million, driven primarily by growth in research income and continued fundraising success.

Research revenue rose significantly due to major funding contributions including Zero Childhood Cancer Program (ZERO) funding, UNSW contract research, and infrastructure support. Fundraising income also increased, supported by major campaigns such as the Minderoo Children’s Comprehensive Cancer Centre (MCCCC) initiative, while maintaining an efficient cost of fundraising below typical industry benchmarks.

Expenses grew in line with increased research activity, particularly within ZERO, alongside higher investment in technology, data, and organisational support.

Overall, the Institute moved from a deficit in 2024 to a surplus of almost $2.1 million in 2025, reflecting improved financial momentum.

The balance sheet reflects continued growth, with total assets rising and equity strengthening over the past three years. While cash and investment balances decreased due to funding major initiatives such as the MCCCC and expanded research programs, receivables increased significantly due to timing of grant income, indicating strong future cash inflows.

Overall, the financial position demonstrates a strategic reinvestment into research capacity and infrastructure, supporting sustained impact and long-term growth.